Drugmakers and biotech companies laid off some 150,000 employees from 2009 through 2012, but now they say they are having trouble attracting top talent, according to a recent PricewaterhouseCoopers report. New drug development models need people who can handle partnerships and collaborative arrangements, as well as skills in biomedical engineering, systems biology, bioinformatics and data analysis, and health economics and outcomes research, according to the report. "What is the industry doing to develop its own people to fill these jobs?" asks Luke Timmerman. "Why can’t at least some of these 150,000 axed people fit into the current openings?" he adds.